PulseAugur
EN
LIVE 01:47:34
中文(ZH) 科兴生物补发财报：2025上半年实现销售额1.303亿美元，同比增1.2%

Isomorphic Labs eyes $2B+ funding as Sinovac Biotech posts modest sales gain amid losses

By PulseAugur Editorial · [1 sources] ·

Isomorphic Labs, an AI-driven drug discovery company spun out of Google DeepMind, is reportedly in advanced talks to raise over $2 billion in a new funding round. Thrive Capital, which led Isomorphic Labs' initial funding, is expected to spearhead this round, with Alphabet also participating. This follows a period where Sinovac Biotech reported a slight increase in sales but a net loss due to asset impairment charges, while also securing its Nasdaq listing. AI

IMPACT Accelerates AI's role in drug discovery, potentially leading to faster development of new therapeutics.

RANK_REASON Significant funding round for an AI-driven drug discovery company.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Isomorphic Labs eyes $2B+ funding as Sinovac Biotech posts modest sales gain amid losses

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Significant
Significant funding round for an AI-driven drug discovery company.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
168 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Sinovac Biotech Resubmits Financial Report: Achieves Sales of $130.3 Million in H1 2025, a 1.2% Increase Year-on-Year

    36氪获悉，科兴生物补发截至2025年6月30日的中期业绩。财报显示，公司上半年实现销售额1.303亿美元，较去年同期的1.287亿美元微增1.2%。然而，受高达6990万美元的资产减值损失影响，出现2170万美元的净亏损。据了解，1月22日，科兴生物公告，公司已正式获得纳斯达克听证委员会批准，将继续维持在纳斯达克全球市场的上市地位，需在5月11日前完成财报报送。

RELATED ENTITIES

RELATED TOPICS